Will We See More Vaccine-Preventable Diseases in the United States?

Rohit Bhalla, DO, Chief of the Section of Infectious Diseases at the University Medical Center of Princeton, discusses if we will see more vaccine-preventable diseases in the United States in the future.

Rohit Bhalla, DO, Chief of the Section of Infectious Diseases at the University Medical Center of Princeton, discusses if we will see more vaccine-preventable diseases in the United States in the future.

Related Videos
Related Content

Who is Most Vulnerable for Long COVID and Can These Factors be Mitigated?

March 23rd 2023

ACIP Preferentially Recommends Fluzone High-Dose Influenza Vaccine for Seniors

June 23rd 2022

Single Dose of Smallpox Vaccine Highly Effective Against Mpox

March 21st 2023

Vaccine Equality vs Equity with Dr. Jacinda Abdul-Mutakabbir

February 11th 2022

Pfizer-BioNTech Omicron Bivalent Booster Receives FDA Emergency Use Authorization for Children Under 5

March 15th 2023

GSK Achieves Primary Endpoints Meningococcal ABCWY Vaccine for Phase 3 Trial

March 15th 2023

Who is Most Vulnerable for Long COVID and Can These Factors be Mitigated?

March 23rd 2023

ACIP Preferentially Recommends Fluzone High-Dose Influenza Vaccine for Seniors

June 23rd 2022

Single Dose of Smallpox Vaccine Highly Effective Against Mpox

March 21st 2023

Vaccine Equality vs Equity with Dr. Jacinda Abdul-Mutakabbir

February 11th 2022

Pfizer-BioNTech Omicron Bivalent Booster Receives FDA Emergency Use Authorization for Children Under 5

March 15th 2023

GSK Achieves Primary Endpoints Meningococcal ABCWY Vaccine for Phase 3 Trial

March 15th 2023

Who is Most Vulnerable for Long COVID and Can These Factors be Mitigated?

March 23rd 2023

ACIP Preferentially Recommends Fluzone High-Dose Influenza Vaccine for Seniors

June 23rd 2022

Single Dose of Smallpox Vaccine Highly Effective Against Mpox

March 21st 2023

Vaccine Equality vs Equity with Dr. Jacinda Abdul-Mutakabbir

February 11th 2022

Pfizer-BioNTech Omicron Bivalent Booster Receives FDA Emergency Use Authorization for Children Under 5

March 15th 2023

GSK Achieves Primary Endpoints Meningococcal ABCWY Vaccine for Phase 3 Trial

March 15th 2023
© 2023 MJH Life Sciences

All rights reserved.